These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30045572)

  • 1. Harvesting the promise of AOPs: An assessment and recommendations.
    Carusi A; Davies MR; De Grandis G; Escher BI; Hodges G; Leung KMY; Whelan M; Willett C; Ankley GT
    Sci Total Environ; 2018 Jul; 628-629():1542-1556. PubMed ID: 30045572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse outcome pathway: a path toward better data consolidation and global co-ordination of radiation research.
    Chauhan V; Beaton D; Hamada N; Wilkins R; Burtt J; Leblanc J; Cool D; Garnier-Laplace J; Laurier D; Le Y; Yamada Y; Tollefsen KE
    Int J Radiat Biol; 2022; 98(12):1694-1703. PubMed ID: 34919011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and application of the adverse outcome pathway framework for understanding and predicting chronic toxicity: I. Challenges and research needs in ecotoxicology.
    Groh KJ; Carvalho RN; Chipman JK; Denslow ND; Halder M; Murphy CA; Roelofs D; Rolaki A; Schirmer K; Watanabe KH
    Chemosphere; 2015 Feb; 120():764-77. PubMed ID: 25439131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing the adverse outcome pathway framework-An international horizon scanning approach.
    LaLone CA; Ankley GT; Belanger SE; Embry MR; Hodges G; Knapen D; Munn S; Perkins EJ; Rudd MA; Villeneuve DL; Whelan M; Willett C; Zhang X; Hecker M
    Environ Toxicol Chem; 2017 Jun; 36(6):1411-1421. PubMed ID: 28543973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Pragmatic Approach to Adverse Outcome Pathway Development and Evaluation.
    Svingen T; Villeneuve DL; Knapen D; Panagiotou EM; Draskau MK; Damdimopoulou P; O'Brien JM
    Toxicol Sci; 2021 Nov; 184(2):183-190. PubMed ID: 34534351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a role for the adverse outcome pathway framework to support radiation protection?
    Chauhan V; Said Z; Daka J; Sadi B; Bijlani D; Marchetti F; Beaton D; Gaw A; Li C; Burtt J; Leblanc J; Desrosiers M; Stuart M; Brossard M; Vuong NQ; Wilkins R; Qutob S; McNamee J; Wang Y; Yauk C
    Int J Radiat Biol; 2019 Feb; 95(2):225-232. PubMed ID: 30373433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How Adverse Outcome Pathways Can Aid the Development and Use of Computational Prediction Models for Regulatory Toxicology.
    Wittwehr C; Aladjov H; Ankley G; Byrne HJ; de Knecht J; Heinzle E; Klambauer G; Landesmann B; Luijten M; MacKay C; Maxwell G; Meek ME; Paini A; Perkins E; Sobanski T; Villeneuve D; Waters KM; Whelan M
    Toxicol Sci; 2017 Feb; 155(2):326-336. PubMed ID: 27994170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Adverse Outcome Pathway: A Multifaceted Framework Supporting 21
    Ankley GT; Edwards SW
    Curr Opin Toxicol; 2018 Jun; 9():1-7. PubMed ID: 29682628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse outcome pathway (AOP) development I: strategies and principles.
    Villeneuve DL; Crump D; Garcia-Reyero N; Hecker M; Hutchinson TH; LaLone CA; Landesmann B; Lettieri T; Munn S; Nepelska M; Ottinger MA; Vergauwen L; Whelan M
    Toxicol Sci; 2014 Dec; 142(2):312-20. PubMed ID: 25466378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high-level overview of the OECD AOP Development Programme.
    Chauhan V; Hamada N; Wilkins R; Garnier-Laplace J; Laurier D; Beaton D; Tollefsen KE
    Int J Radiat Biol; 2022; 98(12):1704-1713. PubMed ID: 35938955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introducing WikiPathways as a Data-Source to Support Adverse Outcome Pathways for Regulatory Risk Assessment of Chemicals and Nanomaterials.
    Martens M; Verbruggen T; Nymark P; Grafström R; Burgoon LD; Aladjov H; Torres Andón F; Evelo CT; Willighagen EL
    Front Genet; 2018; 9():661. PubMed ID: 30622555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Building a Network of Adverse Outcome Pathways (AOPs) Incorporating the Tau-Driven AOP Toward Memory Loss (AOP429).
    Tsamou M; Roggen EL
    J Alzheimers Dis Rep; 2022; 6(1):271-296. PubMed ID: 35891639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When Are Adverse Outcome Pathways and Associated Assays "Fit for Purpose" for Regulatory Decision-Making and Management of Chemicals?
    Coady K; Browne P; Embry M; Hill T; Leinala E; Steeger T; Maślankiewicz L; Hutchinson T
    Integr Environ Assess Manag; 2019 Jul; 15(4):633-647. PubMed ID: 30908812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse outcome pathways (AOPs) for radiation-induced reproductive effects in environmental species: state of science and identification of a consensus AOP network.
    Tollefsen KE; Alonzo F; Beresford NA; Brede DA; Dufourcq-Sekatcheff E; Gilbin R; Horemans N; Hurem S; Laloi P; Maremonti E; Oughton D; Simon O; Song Y; Wood MD; Xie L; Frelon S
    Int J Radiat Biol; 2022; 98(12):1816-1831. PubMed ID: 35976054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translating Scientific Advances in the AOP Framework to Decision Making for Nanomaterials.
    Ede JD; Lobaskin V; Vogel U; Lynch I; Halappanavar S; Doak SH; Roberts MG; Shatkin JA
    Nanomaterials (Basel); 2020 Jun; 10(6):. PubMed ID: 32599945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AOP-DB: A database resource for the exploration of Adverse Outcome Pathways through integrated association networks.
    Pittman ME; Edwards SW; Ives C; Mortensen HM
    Toxicol Appl Pharmacol; 2018 Mar; 343():71-83. PubMed ID: 29454060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse outcome pathway development from protein alkylation to liver fibrosis.
    Horvat T; Landesmann B; Lostia A; Vinken M; Munn S; Whelan M
    Arch Toxicol; 2017 Apr; 91(4):1523-1543. PubMed ID: 27542122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of AOPs to assist regulatory assessment of chemical risks - Case studies, needs and recommendations.
    Bajard L; Adamovsky O; Audouze K; Baken K; Barouki R; Beltman JB; Beronius A; Bonefeld-Jørgensen EC; Cano-Sancho G; de Baat ML; Di Tillio F; Fernández MF; FitzGerald RE; Gundacker C; Hernández AF; Hilscherova K; Karakitsios S; Kuchovska E; Long M; Luijten M; Majid S; Marx-Stoelting P; Mustieles V; Negi CK; Sarigiannis D; Scholz S; Sovadinova I; Stierum R; Tanabe S; Tollefsen KE; van den Brand AD; Vogs C; Wielsøe M; Wittwehr C; Blaha L
    Environ Res; 2023 Jan; 217():114650. PubMed ID: 36309218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AOP-helpFinder webserver: a tool for comprehensive analysis of the literature to support adverse outcome pathways development.
    Jornod F; Jaylet T; Blaha L; Sarigiannis D; Tamisier L; Audouze K
    Bioinformatics; 2022 Jan; 38(4):1173-1175. PubMed ID: 34718414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.